Amersham Imager 600

One Bench at a Time

Amersham Imager 600

Amersham Imager 600 is a sensitive and robust chemiluminescence imager for high-resolution digital imaging of protein and DNA samples in gels and membranes.

  • Intuitive operation: You can operate the instrument from a tablet computer with easy-to-use image analysis software. No prior imager experience or training is required to obtain high-quality results.
  • Excellent performance: Advanced optics provides high-resolution images, high sensitivity, and broad dynamic range.
  • Robustness: An optimal instrument for multi-user labs.
New Generation of LAS

Amersham Imager 600, the successor model of the LAS series, is equipped for chemiluminescence imaging and includes an automatic overlay function that allows simultaneous imaging of a chemiluminescent sample and a colored molecular weight marker.

Intuitive Digital Imagers for High-Quality Results

Amersham Imager 600 series is equipped with a dark sample cabinet, a camera system, filter wheel, light sources, and a built-in computer with control and analysis software. High resolution and precise quantitation of low signals are achieved using a multipurpose 16-bit, 3.2 megapixel super-honeycomb CCD camera fitted with a large aperture f/0.85 FUJINON™ lens. Rapid cooling of the detector makes the imager ready-to-use in less than 5 minutes.

Amersham Imager 600 series is backed by GE Healthcare’s expertise in Western blotting and electrophoresis applications, and can grow with your imaging needs. The system comes in four fully upgradable configurations based on equipped combinations of light sources and filters. All systems can be used for chemiluminescent detection and non-quantitative gel documentation.

Learn more at GE Healthcare

Upcoming Event

  • Reaction before action: new approaches to biomineralization-associated diseases

    12:30-13:30
    10/19/2017
    Daniel Laser, PhD CEO and Co-Founder, Applaud Medical RSVP Applaud Medical is a three-year-old company developing treatments for biomineralization-related diseases. Applaud's products use violent physical effects like cavitation and shock waves to achieve a therapeutic effect, while sparing non-targeted tissue through precise chemical targeting. Applaud's lead product, for low-invasiveness treatment of kidney stones, is currently in clinical trials in Gujarat, India. This seminar will cover technical aspects of combining chemical reactions with mechanical action in both Applaud's products and in a range of other drugs and devices, along with a brief discussion of key commercialization considerations for this uniquely promising product category. About Daniel Laser Daniel Laser is Chief Executive Officer and co-founder of Applaud Medical. Dan also founded Wave 80 Biosciences, a pioneer in detecting HIV during the high-transmission-risk earliest phase of infection, when the immune response is insufficiently advanced for antibody-based methods. He has served as board member or advisor to drug and device companies in fields ranging from autoimmune disease to ophthalmology to cancer. Dan got his start in the medical device field working on haptic feedback for telerobotic surgery systems. Dan holds a Ph.D. in mechanical engineering from Stanford University, where he was a Semiconductor Research Corporation Graduate Fellow. While at Stanford, he was also a MacArthur Affiliate at Stanford’s Center for International Security and Cooperation, developing mathematical models for protecting against threats involving weaponized pathogens.

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter